- Home
- NNVC vs TENX Comparison
NNVC vs TENX Comparison
Compare NNVC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNVC
- TENX
- Stock Information
- Founded
- NNVC 2005
- TENX 1967
- Country
- NNVC United States
- TENX United States
- Employees
- NNVC N/A
- TENX N/A
- Industry
- NNVC Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- NNVC Health Care
- TENX Health Care
- Exchange
- NNVC Nasdaq
- TENX Nasdaq
- Market Cap
- NNVC 23.1M
- TENX 27.3M
- IPO Year
- NNVC N/A
- TENX N/A
- Fundamental
- Price
- NNVC $1.42
- TENX $7.52
- Analyst Decision
- NNVC
- TENX Strong Buy
- Analyst Count
- NNVC 0
- TENX 4
- Target Price
- NNVC N/A
- TENX $16.67
- AVG Volume (30 Days)
- NNVC 120.2K
- TENX 124.9K
- Earning Date
- NNVC 11-13-2025
- TENX 11-12-2025
- Dividend Yield
- NNVC N/A
- TENX N/A
- EPS Growth
- NNVC N/A
- TENX N/A
- EPS
- NNVC N/A
- TENX N/A
- Revenue
- NNVC N/A
- TENX N/A
- Revenue This Year
- NNVC N/A
- TENX N/A
- Revenue Next Year
- NNVC $133.33
- TENX N/A
- P/E Ratio
- NNVC N/A
- TENX N/A
- Revenue Growth
- NNVC N/A
- TENX N/A
- 52 Week Low
- NNVC $0.94
- TENX $3.25
- 52 Week High
- NNVC $1.92
- TENX $7.91
- Technical
- Relative Strength Index (RSI)
- NNVC 47.13
- TENX 76.84
- Support Level
- NNVC $1.36
- TENX $7.45
- Resistance Level
- NNVC $1.46
- TENX $7.91
- Average True Range (ATR)
- NNVC 0.05
- TENX 0.32
- MACD
- NNVC 0.00
- TENX 0.08
- Stochastic Oscillator
- NNVC 47.01
- TENX 79.89
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.